() promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma.
Oncoimmunology
View this publicationOncoimmunology
View this publicationSignal transduction and targeted therapy
View this publicationBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
View this publicationJournal of the American Academy of Dermatology
View this publicationJournal of neuro-oncology
View this publicationJAMA oncology
View this publicationEuropean urology
View this publicationStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
View this publicationClinical cancer research : an official journal of the American Association for Cancer Research
View this publicationCancer research
View this publication